These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 28270010)

  • 1. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part I.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jun; 27(6):733-751. PubMed ID: 28270010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tropomyosin receptor kinase inhibitors: an updated patent review for 2010-2016 - Part II.
    Bailey JJ; Schirrmacher R; Farrell K; Bernard-Gauthier V
    Expert Opin Ther Pat; 2017 Jul; 27(7):831-849. PubMed ID: 28270021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trk kinase inhibitors as new treatments for cancer and pain.
    Wang T; Yu D; Lamb ML
    Expert Opin Ther Pat; 2009 Mar; 19(3):305-19. PubMed ID: 19441906
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tropomyosin receptor kinase inhibitors: an updated patent review for 2016-2019.
    Bailey JJ; Jaworski C; Tung D; Wängler C; Wängler B; Schirrmacher R
    Expert Opin Ther Pat; 2020 May; 30(5):325-339. PubMed ID: 32129124
    [No Abstract]   [Full Text] [Related]  

  • 5. Targeting TRK family proteins in cancer.
    Khotskaya YB; Holla VR; Farago AF; Mills Shaw KR; Meric-Bernstam F; Hong DS
    Pharmacol Ther; 2017 May; 173():58-66. PubMed ID: 28174090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application.
    Yan W; Lakkaniga NR; Carlomagno F; Santoro M; McDonald NQ; Lv F; Gunaganti N; Frett B; Li HY
    J Med Chem; 2019 Feb; 62(4):1731-1760. PubMed ID: 30188734
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyrazolo[1,5-
    Mahajan AT; Shivani ; Datusalia AK; Coluccini C; Coghi P; Chaudhary S
    Molecules; 2024 Jul; 29(15):. PubMed ID: 39124968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.
    McCarthy C; Walker E
    Expert Opin Ther Pat; 2014 Jul; 24(7):731-44. PubMed ID: 24809946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design, synthesis and biological evaluation of macrocyclic derivatives as TRK inhibitors.
    Li P; Cai S; Zhao T; Xu L; Guan D; Li J; Zhou J; Zhang H
    Bioorg Med Chem Lett; 2021 Dec; 53():128409. PubMed ID: 34628036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design and synthesis of a fluorinated quinazoline-based type-II Trk inhibitor as a scaffold for PET radiotracer development.
    Bernard-Gauthier V; Mahringer A; Vesnaver M; Fricker G; Schirrmacher R
    Bioorg Med Chem Lett; 2017 Jun; 27(12):2771-2775. PubMed ID: 28476569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type II & III inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.
    Iliev P; Jaworski C; Wängler C; Wängler B; Page BDG; Schirrmacher R; Bailey JJ
    Expert Opin Ther Pat; 2024 Apr; 34(4):231-244. PubMed ID: 38785069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entrectinib: a potent new TRK, ROS1, and ALK inhibitor.
    Rolfo C; Ruiz R; Giovannetti E; Gil-Bazo I; Russo A; Passiglia F; Giallombardo M; Peeters M; Raez L
    Expert Opin Investig Drugs; 2015; 24(11):1493-500. PubMed ID: 26457764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Optimization and Structure-Activity Relationship Studies of 6,6-Dimethyl-4-(phenylamino)-6
    Pan S; Zhang L; Luo X; Nan J; Yang W; Bin H; Li Y; Huang Q; Wang T; Pan Z; Mu B; Wang F; Tian C; Liu Y; Li L; Yang S
    J Med Chem; 2022 Feb; 65(3):2035-2058. PubMed ID: 35080890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of WO2015042088 A1 - a novel urea-based scaffold for TrkA inhibition.
    Bernard-Gauthier V; Schirrmacher R
    Expert Opin Ther Pat; 2016; 26(2):291-5. PubMed ID: 26561352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural characterization of nonactive site, TrkA-selective kinase inhibitors.
    Su HP; Rickert K; Burlein C; Narayan K; Bukhtiyarova M; Hurzy DM; Stump CA; Zhang X; Reid J; Krasowska-Zoladek A; Tummala S; Shipman JM; Kornienko M; Lemaire PA; Krosky D; Heller A; Achab A; Chamberlin C; Saradjian P; Sauvagnat B; Yang X; Ziebell MR; Nickbarg E; Sanders JM; Bilodeau MT; Carroll SS; Lumb KJ; Soisson SM; Henze DA; Cooke AJ
    Proc Natl Acad Sci U S A; 2017 Jan; 114(3):E297-E306. PubMed ID: 28039433
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loxo TRK inhibitor data wows oncologists.
    Dolgin E
    Nat Biotechnol; 2017 Aug; 35(8):694-695. PubMed ID: 28787403
    [No Abstract]   [Full Text] [Related]  

  • 17. Discovery of the Next-Generation Pan-TRK Kinase Inhibitors for the Treatment of Cancer.
    Liu Z; Yu P; Dong L; Wang W; Duan S; Wang B; Gong X; Ye L; Wang H; Tian J
    J Med Chem; 2021 Jul; 64(14):10286-10296. PubMed ID: 34253025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing algorithm for identification of patients with TRK fusion cancer.
    Penault-Llorca F; Rudzinski ER; Sepulveda AR
    J Clin Pathol; 2019 Jul; 72(7):460-467. PubMed ID: 31072837
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Type I inhibitors of tropomyosin receptor kinase (Trk): a 2020-2022 patent update.
    Jaworski C; Iliev P; Wängler C; Wängler B; Page B; Schirrmacher R; Bailey JJ
    Expert Opin Ther Pat; 2023; 33(7-8):503-521. PubMed ID: 37735897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained blockade of neurotrophin receptors TrkA, TrkB and TrkC reduces non-malignant skeletal pain but not the maintenance of sensory and sympathetic nerve fibers.
    Ghilardi JR; Freeman KT; Jimenez-Andrade JM; Mantyh WG; Bloom AP; Bouhana KS; Trollinger D; Winkler J; Lee P; Andrews SW; Kuskowski MA; Mantyh PW
    Bone; 2011 Feb; 48(2):389-98. PubMed ID: 20854944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.